| Breastmilk is a novel source of stem cells with multilineage differentiation potential F Hassiotou, A Beltran, E Chetwynd, AM Stuebe, AJ Twigger, P Metzger, ... Stem cells 30 (10), 2164-2174, 2012 | 348 | 2012 |
| Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains TJ Stuhlmiller, SM Miller, JS Zawistowski, K Nakamura, AS Beltran, ... Cell reports 11 (3), 390-404, 2015 | 342 | 2015 |
| Epigenetic reprogramming of cancer cells via targeted DNA methylation AG Rivenbark, S Stolzenburg, AS Beltran, X Yuan, MG Rots, BD Strahl, ... Epigenetics 7 (4), 350-360, 2012 | 341 | 2012 |
| Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer S Stolzenburg, MG Rots, AS Beltran, AG Rivenbark, X Yuan, H Qian, ... Nucleic acids research 40 (14), 6725-6740, 2012 | 193 | 2012 |
| Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex JS Zawistowski, SM Bevill, DR Goulet, TJ Stuhlmiller, AS Beltran, ... Cancer discovery 7 (3), 302-321, 2017 | 165 | 2017 |
| Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors A Beltran, S Parikh, Y Liu, BD Cuevas, GL Johnson, BW Futscher, ... Oncogene 26 (19), 2791-2798, 2007 | 119 | 2007 |
| Generation of tumor-initiating cells by exogenous delivery of OCT4transcription factor AS Beltran, AG Rivenbark, BT Richardson, X Yuan, H Quian, JP Hunt, ... Breast cancer research 13, 1-21, 2011 | 115 | 2011 |
| Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer S Stolzenburg, AS Beltran, T Swift-Scanlan, AG Rivenbark, R Rashwan, ... Oncogene 34 (43), 5427-5435, 2015 | 106 | 2015 |
| Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function AS Beltran, LM Graves, P Blancafort Oncogene 33 (39), 4767-4777, 2014 | 95 | 2014 |
| Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor AS Beltran, X Sun, PM Lizardi, P Blancafort Molecular cancer therapeutics 7 (5), 1080-1090, 2008 | 70 | 2008 |
| Suppression of breast tumor growth and metastasis by an engineered transcription factor AS Beltran, A Russo, H Lara, C Fan, PM Lizardi, P Blancafort PloS one 6 (9), e24595, 2011 | 68 | 2011 |
| Pathogenic SPTBN1 variants cause an autosomal dominant neurodevelopmental syndrome MA Cousin, BA Creighton, KA Breau, RC Spillmann, E Torti, S Dontu, ... Nature genetics 53 (7), 1006-1021, 2021 | 63 | 2021 |
| DNMTs and impact of CpG content, transcription factors, consensus motifs, lncRNAs, and histone marks on DNA methylation J Loaeza-Loaeza, AS Beltran, D Hernández-Sotelo Genes 11 (11), 1336, 2020 | 63 | 2020 |
| EMX2 is epigenetically silenced and suppresses growth in human lung cancer J Okamoto, T Hirata, Z Chen, HM Zhou, I Mikami, H Li, A Beltran, ... Oncogene 29 (44), 5969-5975, 2010 | 61 | 2010 |
| GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer SM Bevill, JF Olivares-Quintero, N Sciaky, BT Golitz, D Singh, AS Beltran, ... Molecular Cancer Research 17 (7), 1503-1518, 2019 | 56 | 2019 |
| Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander disease severity RA Battaglia, AS Beltran, S Delic, R Dumitru, JA Robinson, P Kabiraj, ... Elife 8, e47789, 2019 | 54 | 2019 |
| Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors H Lara, Y Wang, AS Beltran, K Juárez-Moreno, X Yuan, S Kato, ... Journal of Biological Chemistry 287 (35), 29873-29886, 2012 | 54 | 2012 |
| Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs) AS Beltran, P Blancafort Epigenetics 6 (2), 224-235, 2011 | 52 | 2011 |
| Expression of the pluripotency transcription factor OCT4 in the normal and aberrant mammary gland F Hassiotou, AR Hepworth, AS Beltran, MM Mathews, AM Stuebe, ... Frontiers in oncology 3, 79, 2013 | 49 | 2013 |
| Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients D Torres, JL Bermejo, MU Rashid, I Briceño, F Gil, A Beltran, V Ariza, ... Scientific reports 7 (1), 4713, 2017 | 48 | 2017 |
Gary l JohnsonUniversity of North Carolina School of Medicineبريد إلكتروني تم التحقق منه على med.unc.edu
